The payer first announced plans to sell the Pittsburgh-based company to Vistria Group, General Atlantic and Nautic Partners in May. It announced the deal along with a seperate sale of Magellan Rx to Prime Therapeutics. The two deals are worth a total of $2.8 billion.
Centene purchased Pantherx in December 2020. The payer said in a July 14 news release it intends to use a majority of the Pantherx sale proceeds to repurchase stock and the balance to reduce debt.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
